LARGE2: A Drug Target / Disease Biomarker (G120071)

Target Name: LARGE2

NCBI ID: G120071

LARGE2

LARGE2: A Drug Target / Disease Biomarker

Large2 (also known as LARGE2A) is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the main functions of Large2 is to control the size and shape of cells. It does this by regulating the activity of several key signaling pathways, including TGF-β, Wnt, and Notch. These pathways are important for cell growth, differentiation, and survival, and Large2 plays a critical role in ensuring that cells are developed and maintained in an appropriate size and shape.

In addition to its role in cell growth and differentiation, Large2 has also been shown to play a key role in the regulation of cellular immigration. This is important for the development and maintenance of tissues and organs, and is also involved in the regulation of inflammation and immune responses.

Due to its involvement in so many important cellular processes, Large2 has been identified as a potential drug target. Researchers are currently working to develop small molecules and other compounds that can inhibit the activity of Large2, with the goal of using these compounds to treat a variety of diseases.

One of the main challenges in developing new treatments for diseases is understanding how the disease works at the molecular level. This is especially important for diseases that are complex and difficult to treat, such as cancer and neurodegenerative diseases. By studying the underlying mechanisms of these diseases, researchers can identify new targets for treatment and develop new compounds that can help to interfere with their development.

Large2 is an important protein that plays a critical role in many cellular processes in the body. It is a potential drug target, and researchers are currently working to develop compounds that can inhibit its activity to treat a variety of diseases. With further research, Large2 may become a valuable tool for the treatment of a wide range of conditions.

Protein Name: LARGE Xylosyl- And Glucuronyltransferase 2

Functions: Bifunctional glycosyltransferase with both alpha-1,3-xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the maturation of alpha-dystroglycan (DAG1) by glycosylation leading to DAG1 binding to laminin G-like domain-containing extracellular proteins with high affinity and in a phosphorylated-O-mannosyl trisaccharide dependent manner (PubMed:15661757, PubMed:15752776, PubMed:25138275). Elongates the glucuronyl-beta-1,4-xylose-beta disaccharide primer structure by adding repeating units [-3-Xylose-alpha-1,3-GlcA-beta-1-] to produce a heteropolysaccharide (By similarity). Supports the maturation of DAG1 more effectively than LARGE1 (PubMed:15752776). In addition, can modify both heparan sulfate (HS)- and chondroitin/dermatan sulfate (CS/DS)-proteoglycans (PGs), namely GPC4, with a glycosaminoglycan (GAG)-like polysaccharide composed of xylose and glucuronic acid to confer laminin binding (By similarity)

The "LARGE2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LARGE2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets